Lack of correlation between serum soluble fas/APO‐1 levels and autoimmune disease

Goel, Niti; Clair, EW St; Fleming, Judith A.; Ulrich, Dawn; Lynch, David H.; Seldin, Michael F.

doi:10.1002/art.1780381206

Cited by 55 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, 2 different groups of investigators reported a lack of correlation between autoimmune disease and serum sFas levels (14,15). Our data extended these early findings by confirming the lack of correlation between serum sFas and disease activity in RA.…”

Section: Discussionsupporting

confidence: 88%

Accumulation of soluble fas in inflamed joints of patients with rheumatoid arthritis

Hasunuma

Kayagaki

Asahara

et al. 1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To examine the concentration of the soluble form of the Fas molecule (sFas) in the serum and synovial fluid of patients with rheumatoid arthritis (RA) and osteoarthritis (OA).Methods. The concentration of sFas in the serum of 15 normal subjects and in the synovial fluid and serum of 45 RA patients and 13 OA patients was determined. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and the level of several cytokines in serum and synovial fluid were also determined.Results. The synovial fluid concentration of sFas was higher in RA than in OA patients (P < 0.005). The Conclusion.Our data suggest that accumulation of sFas in the joint cavity of RA patients may inhibit apoptosis and exacerbate the inflammatory process.

show abstract

Section: Discussionsupporting

confidence: 88%

Accumulation of soluble fas in inflamed joints of patients with rheumatoid arthritis

Hasunuma

Kayagaki

Asahara

et al. 1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…in nonhematopoietic human malignancy (45), in angioimmunoblastic T-cell lymphoma (46), in myocarditis and in patients with congestive heart failure (47,48), and in some patients with rheumatoid arthritis or systemic lupus erythematosus (49, 50, 23). However, it should be noted that increased levels of sCD95 in autoimmune diseases is still controversial; this increase occurred infrequently or was not detected in the serum of patients with rheumatoid arthritis or systemic lupus erythematosus in other studies (51,52).…”

Section: Discussionmentioning

confidence: 94%

Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor

Papoff¹,

Häusler²,

Eramo³

et al. 1999

Journal of Biological Chemistry

154

118

View full text Add to dashboard Cite

The CD95 death receptor plays an important role in several physiological and pathological apoptotic processes involving in particular the immune system. CD95 ligation leads to clustering of the receptor cytoplasmic "death domains" and recruitment of the zymogen form of caspase-8 to the cell surface. Activation of this protease through self-cleavage, followed by activation of downstream effector caspases, culminates in cleavage of a set of cellular proteins resulting in apoptosis with disassembly of the cell. It is very well known that the extracellular region of the CD95 receptor is required for CD95L interaction and that the death domain is necessary for the induction of the apoptotic signaling. Here, we identified and characterized a novel CD95 ligandand death domain-independent oligomerization domain mapping to the NH 2 -terminal extracellular region of the CD95 receptor. In vitro and in vivo studies indicated that this domain, conserved among all soluble CD95 variants, mediates homo-oligomerization of the CD95 receptor and of the soluble CD95 proteins, as well as heterooligomerization of the receptor with the soluble variants. These results offer new insight into the mechanism of apoptosis inhibition mediated by the soluble CD95 proteins and suggest a role of the extracellular oligomerization domain in the regulation of the non-signaling state of the CD95 receptor.Apoptosis is a cell death process that can be elicited by a variety of stimuli, such as growth factor deprivation, ionizing radiation, and other DNA-damaging agents, or by triggering specific cell surface receptors, the death receptors. Death receptors belong to the tumor necrosis factor (TNF) 1 receptor gene superfamily, which is characterized by similar cysteinerich extracellular domains (1). The death receptors TNF-R1 (also called p55 or CD120a), CD95 (also called Fas or Apo-1), DR3 (also called Wsl-1, Apo-3, LARD, or TRAMP), DR4 (also called TRAIL-R1), DR5 (also called Apo-2, TRAIL-R2, TRICK2, or KILLER) (2), and DR6 (3) are also characterized by the presence of a death domain within the cytoplasmic region critical for the initiation of apoptotic signaling (4, 5). Notably, CD95 ligand (CD95L) and CD95 receptor interactions play an important role in the regulation of the immune response and in the control of peripheral B and T cell survival that is critical to the maintenance of immune cell homeostasis (6). This system has also been implicated in maintaining immunoprivilege in the eye and testis (7, 8), attenuating immunosurveillance against certain types of tumors, such as melanoma and hepatocellular carcinoma (9). Moreover, alterations in the control of apoptosis, also mediated by the CD95/CD95L system, are involved in the pathogenesis of several diseases such as Hashimoto thyroiditis (10), fulminant hepatitis (11, 12), and toxic epidermal necrolysis (Lyell's syndrome) (13). Thus, it is particularly interesting to elucidate the mechanisms that regulate CD95 and CD95L interactions.A common feature of the death receptors is that, upon binding to...

show abstract

“…They added evidence that a Fas-Fc fusion protein with a soluble nature evoked autoimmune features in healthy mice. In contrast, Knipping et al [21] and Goel et al [22] recently reported that elevation in sFas levels is a rare feature in SLE and doubted the involvement of sFas in the etiopathogenesis of SLE. To clarify this apparent discrepancy, we designed a sandwich ELISA system to determine serum sFas levels and to characterize the molecular structure of sFas.…”

Section: Introductionmentioning

confidence: 97%

Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases

Jodo

Kobayashi

Kayagaki

et al. 1997

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThere are two major forms of the Fas molecule, membranous Fas and soluble Fas (sFas). To clarify the clinical significance of sFas in autoimmune diseases, we designed a sandwich ELISA to determine serum concentrations of sFas and its molecular structure, and we then analysed the correlation between levels of sFas and laboratory findings in patients with SLE and other autoimmune diseases. The levels of serum sFas were significantly higher in SLE patients than in subjects with other autoimmune diseases and in healthy donors, and the frequency of a positive serum sFas was much greater in SLE patients with high SLE disease activity index scores than in those with low scores. In addition, sFas-positive SLE patients showed a significant difference in various laboratory parameters from sFas-negative SLE patients. Serial measurements of serum sFas levels in SLE patients with active disease revealed that the elevated level of sFas dramatically decreased with improvement in clinical and laboratory findings, following corticosteroid therapy. We propose that the serum level of sFas can serve as an appropriate marker for evaluating SLE disease activity. Serum sFas is heterogeneous with respect to molecular structure, thus several mechanisms are involved in the generation of sFas.

show abstract

Lack of correlation between serum soluble fas/APO‐1 levels and autoimmune disease

Cited by 55 publications

References 15 publications

Accumulation of soluble fas in inflamed joints of patients with rheumatoid arthritis

Accumulation of soluble fas in inflamed joints of patients with rheumatoid arthritis

Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor

Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases

Contact Info

Product

Resources

About